Get the Daily Brief
Latest Biotech News
BioMarin to buy Amicus: $4.8B deal adds Fabry and Pompe drugs
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, bringing two marketed rare‑disease therapies and a late‑stage pipeline asset into its portfolio. The boards of both companies...
Phase III paused: ADC trial halted after deaths
Sponsors halted recruitment and enrollment in a phase III study of the antibody‑drug conjugate (ADC) ifinatamab deruxtecan after a higher‑than‑anticipated incidence of fatal interstitial lung...
FDA clears Cytokinetics’ heart drug – company secures first U.S. approval
The U.S. Food and Drug Administration approved Cytokinetics’ Myqorzo, marking the company’s first U.S. drug approval after a multi‑decade effort. The approval targets obstructive hypertrophic...
Single‑cell translation ramps: FFPE chromatin kit and variant–cell mapping pact
Two announcements signaled expansion of single‑cell capabilities toward clinical and functional genomics. Swedish spinout Epigenovo unveiled its scFFPE‑ATAC assay to profile chromatin...
Galux, Boehringer test AI protein design – partnership for purpose‑built molecules
Galux signed a research agreement with Boehringer Ingelheim to explore AI‑driven protein design for therapeutic applications. The collaboration will evaluate whether generative and predictive...
White House seals nine drug‑pricing pacts: largest batch yet
The White House finalized agreements with nine major drugmakers to lower Medicaid prices to levels paid by peer nations as part of a most‑favored‑nation (MFN) strategy. Companies named in the...
Methylation blood test moves to Pitt: preclinical study for pancreatic cancer
Singlera Genomics and Breakthrough Genomics launched a preclinical collaboration with the University of Pittsburgh to evaluate the BT‑Reveal early pancreatic cancer test, a methylation‑based...
JAX completes NYSCF acquisition – unified nonprofit launches in New York
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a launch event at NYSCF’s Manhattan campus to mark a unified nonprofit research organization. The...
BC Platforms adds GeneVault data – 48M patient multimodal cohort
BC Platforms signed an agreement with GeneVault to integrate multimodal genomic, phenomic and clinical datasets from approximately 48 million patients into BC Unify. The datasets cover...
Harbour inks $90M antibody pact with BMS – multi‑specifics and China strategy
Harbour BioMed and Bristol Myers Squibb signed a discovery and development collaboration centered on next‑generation multi‑specific antibody therapeutics. Harbour will receive $90 million upfront...
BioMarin pays $4.8B for Amicus — rare‑disease portfolio expands
BioMarin agreed to acquire Amicus Therapeutics in an all‑cash deal that values Amicus at roughly $4.8 billion. The boards approved the transaction; BioMarin will take on Amicus’ approved therapies...
Patient deaths prompt partial hold: Merck, Daiichi ADC trial paused
Regulators and sponsors paused enrollment in a Phase III study testing an antibody‑drug conjugate (ADCs) after a cluster of fatal events. Daiichi Sankyo voluntarily put recruitment on hold in the...
FDA greenlights Myqorzo: Cytokinetics lands first US approval
The FDA approved Cytokinetics’ Myqorzo to treat obstructive hypertrophic cardiomyopathy, giving the company its first U.S. drug approval after decades of development. Myqorzo will launch...
Epigenovo targets clinics: single‑cell chromatin assay for FFPE tissue
Epigenovo, a Uppsala University spinout, is commercializing scFFPE‑ATAC — a single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) samples. The startup...
Parse and Codebreaker pair single‑cell scale with variant libraries
Parse Biosciences and Codebreaker Labs launched a collaboration to pair Codebreaker’s engineered variant libraries with Parse’s single‑cell transcriptomics platform to experimentally map how...
Galux and Boehringer ink AI design pact: purposeful proteins next
Galux signed a research agreement with Boehringer Ingelheim to test AI‑driven protein design for therapeutic use cases. The collaboration will validate AI‑designed, purpose‑specific proteins...
Bruker settles with AbCellera — $36M plus royalties to end IP fight
Bruker agreed to pay AbCellera $36 million and royalties to resolve patent litigation tied to microfluidic single‑cell platforms. The settlement covers Bruker’s Beacon‑derived Optofluidic platform...
JAX and NYSCF unify — nonprofit engine for genomics and stem cells
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and formally launched the unified nonprofit organization in New York. JAX leaders said the integration pairs...
Nonprofit rescues abandoned gene therapy — can the model scale?
A nonprofit effort brought an orphaned rare‑disease gene therapy to market by rescuing development and facilitating access, according to BioCentury’s reporting. The case involved Fondazione...
FDA issues two Form 483s to Catalent’s Maryland gene‑therapy sites
The FDA issued two Form 483 observations to Catalent’s Maryland facilities that manufacture gene‑therapy products prior to a round of mass layoffs at the sites. The notices relate to manufacturing...